Abstract Library

#3072 Rb and p53 Status Determination by Immunochemistry Is Complementary in Routine Practice to Genetic Testing of Neuroendocrine Neoplasms

Introduction: Rb and p53 status may help distinguishing well from poorly differentiated neuroendocrine neoplasms (NEN) and may predict response to chemotherapy. Studies correlating Rb/p53 genetic and immunohistochemistry were performed on high-quality frozen samples with high throughput techniques efficient for copy number determination. This situation differs from routine practice in which small deletions may be hard to detect on formalin-fixed paraffin-embedded (FFPE) samples with a gene panel approach.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cros J

Authors: Chen R, Lacroix L, De Rycke O, Lacombe C, Cazes A,

Keywords: rb, p53, aggressive neuroendocrine tumors, biomarker,

#3068 WHO Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasm (GEP-NEN): Data from 358 Patients of the Spanish Group of Neuroendocrine and Endocrine Tumors Registry (R-GETNE)

Introduction: RGETNE national NEN Registry comprises 74 hospitals from all regions of Spain.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Garcia Carbonero R, Jimenez-Fonseca P, Benavent M, Alonso V, Crespo G,

Keywords: G3 NEN, epidemiology, survival, patterns of care, response to chemotherapy,

#1688 Pancreatic NET-G3 Does Not Respond to Platinum-Based Chemotherapy: A Multicenter Study of Neuroendocrine Carcinomas

Introduction: Recent studies　have shown that Pancreatic neuroendocrine carcinomas (NECs) contain well-differentiated NETs with high proliferative activity (WDNET-G3), as well as poorly differentiated NECs (PDNECs). Although patients with pNEC show variable responses to platinum-based chemotherapy, predictors of the response are unknown.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Hijioka S

Authors: Hijioka S, Hosoda W, Matsuo k, Ueno M, Furukawa M,

Keywords: NET G3, NEC, KRAS, Rb,

#1687 Pancreatic well-differentiated neuroendocrine tumor with grade 3 does not respond to platinum-based chemotherapy: a multicenter study of neuroendocrine carcinomas

Introduction: Recent studies　have shown that Pancreatic neuroendocrine carcinomas (NECs) contain well-differentiated NETs with high proliferative activity (WDNET-G3), as well as poorly differentiated NECs (PDNECs). Although patients with pNEC show variable responses to platinum-based chemotherapy, predictors of the response are unknown.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Hijioka S

Authors: Hijioka S,

Keywords: NET-G3, NEC, KRAS, Rb,

#1381 [18F]FDG-PET/CT as a Predictive Tool for Response to Chemotherapy and Everolimus Treatment in Patientes with Pancreatic Neuroendocrine Tumour

Introduction: The predictive role of 18F-FDG-PET/CT (FP) in neuroendocrine tumours is debated.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Ortolani S

Authors: Ortolani S, Cingarlini S, Citton E, Crosara S, De Robertis R,

Keywords: 18F-FDG-PET/CT, predictive, chemotherapy, everolimus, pancreatic NETs,